miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo

Kai Liu1, Bingsen He1, Jiang Xu1

  • 1Department of Pediatrics, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).

Insights

MicroRNA-483-5p is downregulated in pediatric Wilms tumor. Restoring its levels inhibits tumor growth by promoting apoptosis, offering a potential new treatment strategy for this rare cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Wilms tumor (WT) is a prevalent pediatric renal malignancy with significant mortality.
  • MicroRNAs (miRNAs) are key regulators of cellular processes implicated in tumorigenesis.

Purpose of the Study:

  • To investigate the role of miR-483-5p in Wilms tumor development and progression.
  • To explore the therapeutic potential of modulating miR-483-5p in Wilms tumor.

Main Methods:

  • Quantitative analysis of miR-483-5p expression in 28 Wilms tumor tissues and adjacent normal tissues.
  • In vitro studies using miR-483-5p mimics in the GHINK-1 Wilms tumor cell line to assess proliferation and apoptosis.
  • In vivo validation in a mouse model (BALB/c nu/nu) to confirm the effects of miR-483-5p.

Main Results:

  • miR-483-5p was significantly downregulated in Wilms tumor tissues compared to normal tissues.
  • Low miR-483-5p expression correlated with unfavorable histology, lymphatic metastasis, and advanced clinical stage (III/IV).
  • Overexpression of miR-483-5p suppressed Wilms tumor cell proliferation and colony formation by inducing apoptosis and upregulating caspase-3.

Conclusions:

  • miR-483-5p acts as a tumor suppressor in Wilms tumor by inhibiting proliferation and promoting apoptosis.
  • MAP kinase-interacting serine/threonine-protein kinase 1 (MKNK1) was identified as a direct target of miR-483-5p.
  • miR-483-5p represents a potential therapeutic target for Wilms tumor treatment.